Critical Assessment of Belgian Reimbursement Dossiers of Orphan Drugs

@article{Denis2011CriticalAO,
  title={Critical Assessment of Belgian Reimbursement Dossiers of Orphan Drugs},
  author={Alain Denis and Lut Mergaert and Christel Fostier and Irina Cleemput and Frank Hulstaert and Professor Dr Steven Simoens},
  journal={PharmacoEconomics},
  year={2011},
  volume={29},
  pages={883-893}
}
Background: Orphan medicinal products are designed to diagnose or treat rare diseases that are serious, life threatening or chronically debilitating and that affect 50 or fewer people in every 100 000 in the EU. In Belgium, the Drug Reimbursement Committee (DRC) evaluates reimbursement requests for orphan drugs based on multiple criteria: the therapeutic value, price and proposed reimbursement tariff; the importance of the drug in clinical practice; and the budget impact of the drug. Objectives… CONTINUE READING
9 Citations
7 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-7 of 7 references

Regulation (EC) No 141/2000 of the European Parliament and the Council of 16 December 1999 on orphan medicinal products

  • European Commission
  • Official J European Communities
  • 2000
Highly Influential
3 Excerpts

A comparative study of European rare disease and orphan drug markets

  • A deVarax, M Letellier, G Börtlein
  • Health Policy
  • 2010

Guidelines for pharmaco-economic evaluation in Belgium

  • I Cleemput, P Van Wilder, F Vrijens
  • Brussels: Belgian Health Care Knowledge Centre,
  • 2008
1 Excerpt

Study on orphan drugs. Phase I: overview of the conditions for marketing orphan drugs in Europe

  • A de Varax, M Letellier, G. Börtlein
  • Paris: Alcimed,
  • 2006
1 Excerpt

Similar Papers

Loading similar papers…